GlassScriptPhysician profile
Hetal A Karsan
NPI 1063402881
$313,986.99
in general payments reported to CMS, 2019-2025
49 companies · $62K in 2025
The $62K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61K · 2020: $11K · 2021: $35K · 2022: $63K · 2023: $49K · 2024: $32K · 2025: $62K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $112K · Consulting Fee: $11K · Food and Beverage: $8,438 · Travel and Lodging: $8,129 · Honoraria: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $111,831.50 |
| Consulting Fee | $11,480.00 |
| Food and Beverage | $8,438.48 |
| Travel and Lodging | $8,129.20 |
| Honoraria | $3,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $93,746.12 | 2019-2025 | |
| Gilead Sciences, INC. | $60,852.38 | 2019-2025 | Epclusa, Livdelzi |
| Mallinckrodt Hospital Products INC. | $47,504.02 | 2021-2025 | Terlivaz |
| Madrigal Pharmaceuticals | $30,781.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Ipsen Biopharmaceuticals, INC | $27,588.15 | 2023-2025 | Iqirvo, Bylvay |
| Intercept Pharmaceuticals, INC. | $15,167.06 | 2019-2024 | Ocaliva |
| Shire North American Group INC | $7,088.08 | 2019 | |
| Exact Sciences Corporation | $7,064.92 | 2023-2025 | Cologuard Collection Kit |
| Alexion Pharmaceuticals, INC. | $4,497.89 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,534.00 | 2025 | |
| Dova Pharmaceuticals | $3,302.01 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $3,242.61 | 2019-2025 | Xifaxan, Plenvu, Trulance |
| Orphalan INC | $3,210.72 | 2023-2025 | Cuvrior |
| Ardelyx, INC. | $2,498.51 | 2022-2025 | Ibsrela |
| Genzyme Corporation | $510.73 | 2022-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hetal Karsan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.